Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), NuVasive (NUVA) and G1 Therapeutics (GTHX).
Alnylam Pharma (ALNY)
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $190.00. The company’s shares closed last Wednesday at $145.27, close to its 52-week high of $151.84.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of 5.0% and a 45.9% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Arcturus Therapeutics, and NeuBase Therapeutics.
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $150.70, which is a 6.7% upside from current levels. In a report issued on April 24, Evercore ISI also initiated coverage with a Buy rating on the stock with a $160.00 price target.
See today’s analyst top recommended stocks >>
NuVasive (NUVA)
In a report released today, Michael Matson from Needham maintained a Hold rating on NuVasive. The company’s shares closed last Wednesday at $56.81.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 5.7% and a 56.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NuVasive with a $69.18 average price target.
G1 Therapeutics (GTHX)
Needham analyst Chad Messer reiterated a Buy rating on G1 Therapeutics today and set a price target of $74.00. The company’s shares closed last Wednesday at $13.94, close to its 52-week low of $8.81.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 10.7% and a 47.0% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics with a $78.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
